title: [Therapeutic effect of levamisole plus HBV vaccine and dipyridamole on patients chronically infected by HBV with precore mutation].
abstract: OBJECTIVE
  To evaluate the incidence of precore mutation in HBeAg negative HBV infected patients and the therapeutic effect of the immune therapy (levamisole + HBV vaccine + dipyridamole) on patients chronically infected by HBV with precore mutation.
  
  
  METHODS
  The precore region of HBV from the HBeAg (-) chronic hepatitis patients was sequenced and the patients suffered from HBV with precore mutation were treated with immune therapy.
  
  
  RESULTS
  The precore mutation rate was 10/12. The therapeutic effect of the immune therapy on the precore mutation patients (5/7) was better than that on the HBsAg(+), HBeAg(+) patients (2/11), P less than 0.05.
  
  
  CONCLUSIONS
  The precore mutation rate was quite high in the HBsAg(+), HBeAg(-) patients we studied. The immune-therapy has some therapeutic effects on the patients with precore mutation. But the number of cases was too small, further study is needed.
authors.affiliation: The Third Peoples Hospital, Wuhu Anhui 241000, China.
authors.forename: Xiao-lian
authors.initials: XL
authors.lastname: Luo
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Geng-shan
authors.initials: GS
authors.lastname: Tian
authors.forename: Xi-xian
authors.initials: XX
authors.lastname: Fu
authors.forename: Yong-yi
authors.initials: YY
authors.lastname: Wang
authors.forename: Lai
authors.initials: L
authors.lastname: Wei
authors.forename: Jie
authors.initials: J
authors.lastname: Chen
authors.forename: Sheng
authors.initials: S
authors.lastname: Su
authors.forename: Gong-ren
authors.initials: GR
authors.lastname: Fan
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D003131:Combined Modality Therapy; D004279:DNA, Viral / Q000097:blood; D004176:Dipyridamole / Q000627:therapeutic use*; D017325:Hepatitis B Vaccines / Q000627:therapeutic use*; D006515:Hepatitis B virus / Q000235:genetics / Q000302:isolation & purification; D019694:Hepatitis B, Chronic / Q000628:therapy* / Q000821:virology; D006801:Humans; D007167:Immunotherapy; D019259:Lamivudine / Q000627:therapeutic use; D007978:Levamisole / Q000627:therapeutic use*; D008875:Middle Aged; D009154:Mutation
chemical_list: D004279:DNA, Viral; D017325:Hepatitis B Vaccines; D007978:Levamisole; D019259:Lamivudine; D004176:Dipyridamole